---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-23-000219"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T03:12:03.031508+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Lilly Q2 revenue $8.31B (+28%), EPS $1.95 (+86%), raises FY guidance

## Summary
- Q2 revenue $8,312M, up 28% YoY; reported EPS $1.95 (+86%); non-GAAP EPS $2.11 (+69%, includes $0.43 from Baqsimi rights sale).
- FY 2023 reported EPS guidance raised to $9.20-$9.40; non-GAAP EPS raised to $9.70-$9.90, up $1.02 and $1.05 respectively.
- Mounjaro led New Products with $1.00B revenue; Growth Products up 16% to $4.93B, led by Verzenio, Jardiance, Taltz.
- Pipeline progress: donanemab submitted to FDA/EMA for Alzheimer's; tirzepatide submitted for chronic weight management; mirikizumab approved in EU.
- Announced agreements to acquire DICE Therapeutics, Sigilon Therapeutics, and Versanis Bio to expand autoimmune and cardiometabolic pipeline.

## SEC filing metadata
- accession: 0000059478-23-000219
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947823000219/0000059478-23-000219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947823000219/lly-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-23-000219
- JSON: https://secwatch.observer/filing/0000059478-23-000219.json
- Plain text: https://secwatch.observer/filing/0000059478-23-000219.txt

## Key facts
- Earnings Releases
  ELI LILLY & Co reported the second quarter of 2023 results: revenue $8,312.1, net income $1,763.2, EPS $1.95. Guidance raised.
  - Period: the second quarter of 2023
  - Revenue: $8,312.1
  - Net income: $1,763.2
  - EPS: $1.95
  - Guidance: raised
  - Result: reported results
  source text: on important public announcements, visit the news section of Lilly's website. 2 Financial Results $ in millions, except per share data Second Quarter 2023 2022 % Change Revenue $8,312.1 $6,488.0 28% Net Income – Reported 1,763.2 952.5 85% EPS – Reported 1.95 1.05 86% Net Income – Non-GAAP 1,904.4 1,131.3 68% EPS – Non-GAAP 2.11 1.25 69% A discussion of the
  evidence_url: https://www.sec.gov/Archives/edgar/data/59478/000005947823000219/0000059478-23-000219-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.